User:Mr. Ibrahem/Defibrotide

Defibrotide, sold under the brand name Defitelio, is a medication used to treat veno-occlusive disease of the liver following bone marrow transplant. It is given by injection into a vein. High quality evidence to support its use is lacking.

Common side effects include low blood pressure, nausea, and bleeding. Other side effects may include allergic reactions. It should not be used in people on blood thinners. It is a mixture of oligonucleotides and is believed to work in part by decreasing endothelial cell activation.

Defibrotide was approved for medical use in Europe in 2013, the United States in 2016, and Australia in 2020. In the United States 25 doses of 200 mg cost about 10,000 USD.